Reappraisal on pharmacological and mechanical treatments of heart failure

Cardiovasc Diabetol. 2020 May 6;19(1):55. doi: 10.1186/s12933-020-01024-5.

Abstract

Heart failure (HF) is a highly frequent disorder with considerable morbidity, hospitalization, and mortality; thus, it invariably places pressure on clinical and public health systems in the modern world. There have been notable advances in the definition, diagnosis, and treatment of HF, and newly developed agents and devices have been widely adopted in clinical practice. Here, this review first summarizes the current emerging therapeutic agents, including pharmacotherapy, device-based therapy, and the treatment of some common comorbidities, to improve the prognosis of HF patients. Then, we discuss and point out the commonalities and areas for improvement in current clinical studies of HF. Finally, we highlight the gaps in HF research. We are looking forward to a bright future with reduced morbidity and mortality from HF.

Keywords: Comorbidities; Devices; Heart failure; Management; Pharmacotherapy; Prognosis; Treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cardiac Resynchronization Therapy Devices
  • Cardiac Resynchronization Therapy* / adverse effects
  • Cardiac Resynchronization Therapy* / mortality
  • Cardiovascular Agents / adverse effects
  • Cardiovascular Agents / therapeutic use*
  • Comorbidity
  • Defibrillators, Implantable
  • Electric Countershock* / adverse effects
  • Electric Countershock* / instrumentation
  • Electric Countershock* / mortality
  • Electric Stimulation Therapy* / adverse effects
  • Electric Stimulation Therapy* / instrumentation
  • Heart Failure / diagnosis
  • Heart Failure / mortality
  • Heart Failure / physiopathology
  • Heart Failure / therapy*
  • Heart-Assist Devices
  • Humans
  • Recovery of Function
  • Risk Factors
  • Treatment Outcome
  • Vagus Nerve Stimulation
  • Ventricular Function, Left / drug effects*

Substances

  • Cardiovascular Agents